Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome (TRAPS)
Arthritis & Rheumatism, 11/09/2011
Bulua AC et al. – Etanercept reduces symptoms and serum inflammatory markers of TRAPS in a dose–dependent manner, but does not completely normalize symptoms or acute phase reactants. Although long–term adherence to etanercept is poor, remaining on etanercept may provide continued symptomatic benefit.
Fifteen patients with TRAPS were enrolled in a prospective, open–label, dose–escalation study.
Patients recorded attacks, symptom severity, and use of ancillary medications in a daily diary.
Blood samples were collected during each period and measured for acute phase reactants.
7–9 years after the conclusion of the initial study, patients completed a follow–up survey and were evaluated to determine the long–term outcome of etanercept treatment.
Etanercept treatment significantly attenuated the total symptom score, as well as reduced the frequency of symptoms.
Etanercept also reduced acute phase reactants, particularly during asymptomatic periods.
During a ten–year follow–up period, patients remained on etanercept for a median of 3.3 years, with a number of patients switching to anti–IL–1β therapy or remaining off biologic agents, citing injection reactions and lack of efficacy most frequently for discontinuation.
Patients remaining on etanercept had reduced symptoms at follow–up.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.